References
- Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, Freitas CS, Marcon R, Calixto JB. 2016. Non-clinical studies in the process of new drug development—part II: good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res. 49(12):e5646. doi:10.1590/1414-431X20165646.
- Astrup A, Aruoma OI. 2020. Calcium supplementation and coronary artery disease: time to act? J Am Coll Nutr. 39(4):287–289. doi:10.1080/07315724.2019.1656914.
- Avery RJ, Eisenberg MD, Cantor JH. 2017. An examination of structure-function claims in dietary supplement advertising in the U.S.: 2003-2009. Prev Med. 97:86–92. doi:10.1016/j.ypmed.2017.01.008.
- Best CBD Oil for Anxiety & Depression [Internet]. Discover Magazine. [cited 2020 Jun 3]. https://www.discovermagazine.com/health/best-cbd-oil-for-anxiety-and-depression.
- Bjelakovic G, Nikolova D, Gluud C. 2014. Antioxidant supplements and mortality. Curr Opin Clin Nutr Metab Care. 17(1):40–44. doi:10.1097/MCO.0000000000000009.
- Bleys J. 2008. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 168(4):404. doi:10.1001/archinternmed.2007.74.
- Bracken MB. 2009. Why are so many epidemiology associations inflated or wrong? Does poorly conducted animal research suggest implausible hypotheses? Ann Epidemiol. 19(3):220–224. doi:10.1016/j.annepidem.2008.11.006.
- Brown P. 2017. Drug Approval Package: Epidiolex (Cannabidiol) [Internet]. FDA; [cited 2020 May 13]. https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/milestones-us-food-and-drug-law-history.
- Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafò MR. 2013. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 14(5):365–376. doi:10.1038/nrn3475.
- CBD dosage—how much CBD oil should I take? [Internet]. CBD oil review; [cited 2018 Apr 22]. https://cbdoilreview.org/cbd-cannabidiol/cbd-dosage/.
- CBD Laws by State [Internet]. 2020. CBD Awareness Project. [cited 2020 Jun 11]. https://www.cbdoil.org/cbd-laws-by-state/.
- Cogan PS. 2020. The ‘entourage effect’ or ‘hodge-podge hashish’: the questionable rebranding, marketing, and expectations of cannabis polypharmacy. Expert Rev Clin Pharmacol. 0:1–11.
- Cohen PA, Maller G, DeSouza R, Neal-Kababick J. 2014. Presence of banned drugs in dietary supplements following FDA recalls. JAMA. 312(16):1691–1693. doi:10.1001/jama.2014.10308.
- Cohen PJ. 2005. Science, politics, and the regulation of dietary supplements: it’s time to repeal DSHEA. Am J Law Med. 31(2–3):175–214. doi:10.1177/009885880503100203.
- Dietary Supplement Health and Education Act of 1994 [Internet]. 21 U.S.C. 321 Section 201()1)(c); [cited 2020 Jun 15]. https://ods.od.nih.gov/About/DSHEA_Wording.aspx.
- Dietary Supplement Health and Education Act of 1994 [Internet]. 21 U.S.C. 342 Section 402(f)(1); [cited 2020 Jun 15].
- Dietary Supplement Health and Education Act of 1994 [Internet]. 21 U.S.C. 321 Section 201(ff)(3)(B)(i); [cited 2020 Jun 15]. https://ods.od.nih.gov/About/DSHEA_Wording.aspx.
- DiMasi JA, Grabowski HG, Hansen RW. 2016. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 47:20–33. doi:10.1016/j.jhealeco.2016.01.012.
- Dziwenka M, Coppock R, Alexander M, Palumbo E, Ramirez C, Lermer S. 2020. Safety assessment of a hemp extract using genotoxicity and oral repeat-dose toxicity studies in sprague-dawley rats. Toxicol Rep. 7:376–385. doi:10.1016/j.toxrep.2020.02.014.
- Ekar T, Kreft S. 2019. Common risks of adulterated and mislabeled herbal preparations. Food Chem Toxicol. 123:288–297. doi:10.1016/j.fct.2018.10.043.
- Faustman C, Aaron D, Negowetti N. 2020. Ten years post-GAO assessment, FDA remains uninformed of potentially harmful GRAS substances in foods. Crit Rev Food Sci Nutr. 0:1–9.
- Frank C, Himmelstein DU, Woolhandler S, Bor DH, Wolfe SM, Heymann O, Zallman L, Lasser KE. 2014. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Aff (Millwood). 33(8):1453–1459. doi:10.1377/hlthaff.2014.0122.
- Freedman D, Patel A. 2018. Inadequate regulation contributes to mislabeled online cannabidiol products. Pediatr Neurol Briefs. 32(0):3. [cited 2018 Jul 6]. http://www.pediatricneurologybriefs.com/articles/10.15844/pedneurbriefs-32-3/. [Mismatch] doi:10.15844/pedneurbriefs-32-3.
- Goyal A, Terry MB, Siegel AB. 2013. Serum antioxidant nutrients, vitamin A, and mortality in U.S. adults. Cancer Epidemiol Biomarkers Prev. 22(12):2202–2211. doi:10.1158/1055-9965.EPI-13-0381.
- Greenwich Bioscience. 2020. EPIDIOLEX—cannabidiol solution [Internet]. Dailymed; [cited 2019 Mar 23]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097fb--
- Gupta S. 2014. Medical marijuana and the entourage effect [Internet]. CNN; [cited 2019 Jul 21]. https://www.cnn.com/2014/03/11/health/gupta-marijuana-entourage/index.html.
- Grand View Research. Cannabidiol Market Size | CBD Industry Growth Report, 2019-2025 [Internet]. 2019. [cited 2020 Jun 10]. https://www.grandviewresearch.com/industry-analysis/cannabidiol-cbd-market.
- Guth BD, Pugsley MK. 2017. GLP in safety pharmacology studies: report card after 15years. J Pharmacol Toxicol Methods. 87:24–26. doi:10.1016/j.vascn.2017.02.016.
- Harrison RK. 2016. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov. 15(12):817–818. doi:10.1038/nrd.2016.184.
- Hasler CM. 2008. Health claims in the United States: an aid to the public or a source of confusion? J Nutr. 138(6):1216S–1220S. doi:10.1093/jn/138.6.1216S.
- Huestis M A, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò F P. 2019. Cannabidiol Adverse Effects and Toxicity. Current Neuropharmacology. Curr Neuropharmacol. 17(10):974–989. doi:10.2174/1570159X17666190603171901. 31161980
- Hutchison KE, Bidwell LC, Ellingson JM, Bryan AD. 2019. Cannabis and health research: rapid progress requires innovative research designs. Value Health. 22(11):1289–1294. doi:10.1016/j.jval.2019.05.005.
- Ioannidis J. 2005. Why most published research findings are false. PLoS Med. 2(8):e124. doi:10.1371/journal.pmed.0020124.
- Jüni P, Altman DG, Egger M. 2001. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 323(7303):42–46. doi:10.1136/bmj.323.7303.42.
- Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. 2004. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet. 364(9450):2021–2029. doi:10.1016/S0140-6736(04)17514-4.
- Kees J, Fitzgerald P, Dorsey JD, Hill RP. 2020. Evidence-based cannabis policy: a framework to guide marketing and public policy research. J Public Policy Marketing. 39(1):76–92. doi:10.1177/0743915619848422.
- Lee MA. 2019. CBD & Cannabis Dosing [Internet]. Project CBD; [cited 2020 Jun 11]. https://www.projectcbd.org/how-to/cbd-dosage-guide.
- Lindner MD. 2007. Clinical attrition due to biased preclinical assessments of potential efficacy. Pharmacol Ther. 115(1):148–175. doi:10.1016/j.pharmthera.2007.05.002.
- Lipinski CA. 2004. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 1(4):337–341. doi:10.1016/j.ddtec.2004.11.007.
- Lopez HL, Cesareo KR, Raub B, Kedia W, Sandrock JE, Kerksick CM, Ziegenfuss TN. 2020. Effects of hemp extract on markers of wellness, stress resilience, recovery and clinical biomarkers of safety in overweight, but otherwise healthy subjects. J Dietary Suppl. 0:1–26.
- Lowenstein P R, Castro M G. 2009. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?. Current Gene Therapy. Curr Gene Ther. 9(5):368–374. doi:10.2174/156652309789753392. 19860651
- Lua J, Olney L, Isles C. 2019. Cannabis hyperemesis syndrome: still under recognised after all these years. J R Coll Physicians Edinb. 49(2):132–134. doi:10.4997/JRCPE.2019.210.
- Mak IW, Evaniew N, Ghert M. 2014. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 6(2):114–118.
- Marinotti O, Sarill M. 2020. Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science. Journal of Dietary Supplements. J Diet Suppl. :1–10. doi:10.1080/19390211.2020.1776806. 32543253
- Martínez ME, Jacobs ET, Baron JA, Marshall JR, Byers T. 2012. Dietary supplements and cancer prevention: balancing potential benefits against proven harms. J Natl Cancer Inst. 104(10):732–739. doi:10.1093/jnci/djs195.
- Marx TK, Reddeman R, Clewell AE, Endres JR, Béres E, Vértesi A, Glávits R, Hirka G, Szakonyiné IP. 2018. An assessment of the genotoxicity and subchronic toxicity of a supercritical fluid extract of the aerial parts of hemp. J Toxicol [Internet]. 2018:1–26. [cited 2020 May 12]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011091/. doi:10.1155/2018/8143582.
- Mazuz M, Tiroler A, Moyal L, Hodak E, Nadarajan S, Vinayaka AC, Gorovitz-Haris B, Lubin I, Drori A, Drori G, et al. 2020. Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo. Oncotarget. 11(13):1141–1156. doi:10.18632/oncotarget.27528.
- McPartland JM, Russo EB. 2001. Cannabis and cannabis extracts. J Cannabis Ther. 1(3–4):103–132. doi:10.1300/J175v01n03_08.
- Medical Conditions. 2020. Project CBD [Internet]. [cited 2020 Apr 25]. https://www.projectcbd.org/conditions-hub.
- Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O'Sullivan SE. 2019. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol. 85(9):1888–1900. doi:10.1111/bcp.14038.
- Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. 2005. Meta-analysis: high-dosage vitamin e supplementation may increase all-cause mortality. Ann Intern Med. 142(1):37–46. doi:10.7326/0003-4819-142-1-200501040-00110.
- Mishra KP, Ganju L, Sairam M, Banerjee PK, Sawhney RC. 2008. A review of high throughput technology for the screening of natural products. Biomed Pharmacother. 62(2):94–98. doi:10.1016/j.biopha.2007.06.012.
- Nelson R. 2004. FDA issues alert on ephedra supplements in the USA. The Lancet. 363(9403):135. doi:10.1016/S0140-6736(03)15315-9.
- Peterson CC. 2020. H.R.5587—116th Congress (2019-2020): to amend the Federal Food, Drug, and Cosmetic Act with respect to the regulation of hemp-derived cannabidiol and hemp-derived cannabidiol containing substances [Internet]. [cited 2020 Jun 10]. https://www.congress.gov/bill/116th-congress/house-bill/5587.
- Proschan MA, Waclawiw MA. 2000. Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials. 21(6):527–539. doi:10.1016/S0197-2456(00)00106-9.
- Psaty BM, Vandenbroucke JP. 2008. Opportunities for enhancing the FDA guidance on pharmacovigilance. JAMA. 300(8):952–954. doi:10.1001/jama.300.8.952.
- Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. 2011. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf. 20(7):772–777. doi:10.1002/pds.2155.
- Rahn, Bailey. What Is the Entourage Effect in Cannabis? [Internet]. 2020. Leafly; [cited 2020 Jul 4].
- Rivera SM, Gilman AG. 2017. Goodman & Gilman’s: the pharmacological basis of therapeutics [Internet]. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Drug invention and the pharmaceutical industry. 13th ed. New York (NY): McGraw-Hill Education; p. 3. [cited 2020 May 15]. https://accessmedicine.mhmedical.com/content.aspx?aid=1162532455.
- Russo EB. 2011. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344–1364. doi:10.1111/j.1476-5381.2011.01238.x.
- Schmitz SM, Lopez HL, Marinotti O. 2020. Post marketing safety of plus CBDTM products, a full spectrum hemp extract: a 2-year experience. J Dietary Suppl. 0:1–12.
- Sponsor HT. 2020. The best CBD oil of the year—where to find top products [Internet]. High Times. [cited 2020 Jun 3]. https://hightimes.com/sponsored/best-cbd-oil-year-where-find-top-products/.
- Starr RR. 2015. Too little, too late: ineffective regulation of dietary supplements in the United States. Am J Public Health. 105(3):478–485. doi:10.2105/AJPH.2014.302348.
- Stearns FA. 2005. Federal Court Limits FDA’s Ephedra Ban and Severely Questions the Standard for Finding That Dietary Supplements Present an “Unreasonable” Risk of Illness or Injury [Internet]. Keller & Heckman LLP; [cited 2020 May 15]. https://www.khlaw.com/1276.
- Sterne JAC, Cox DR, Smith GD. 2001. Sifting the evidence-what's wrong with significance tests? BMJ. 322(7280):226–231. doi:10.1136/bmj.322.7280.226.
- Sulak, Dustin. A Physician’s Perspective on Optimal Cannabis Dosing [Internet]. 2018. Leafly; [cited 2020 Jun 11].
- The Center for Applied Health Sciences, LLC. 2020. Effects of Hemp Oil on Markers of Optimal Wellness, Stress Resilience and Recovery in Healthy Subjects [Internet]. clinicaltrials.gov; [cited 2020 Jun 8]. Report No.: NCT04294706. https://clinicaltrials.gov/ct2/show/NCT04294706.
- Timbo BB, Chirtel SJ, Ihrie J, Oladipo T, Velez-Suarez L, Brewer V, Mozersky R. 2018. Dietary supplement adverse event report data from the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004-2013. Ann Pharmacother. 52(5):431–438. doi:10.1177/1060028017744316.
- U.S. Food & Drug Administration. 2019. Public health focus—warning letters and test results for cannabidiol-related products [Internet]. FDA; [cited 2018 Jun 12]. https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm484109.htm.
- U.S. Food & Drug Administration. 2016. Draft guidance for industry: new dietary ingredient notifications and related issues [Internet]. FDA; [cited 2020 May 14]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance- industry-new-dietary-ingredient-notifications-and-related-issues.
- U.S. Food & Drug Administration. 2018. Indications and usage section of labeling for human prescription drug and biological products—content and format guidance for industry [Internet]. FDA; [cited 2020 May 12]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/indications-and-usage-section-labeling-human-prescription-drug-and-biological-products-content-and.
- U.S. Food & Drug Administration. 2015. IND application reporting: safety reports. FDA [Internet]. [cited 2020 May 12]. https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-reporting-safety-reports.
- U.S. Food & Drug Administration. 2018. Milestones in U.S. Food and Drug Law History [Internet]. FDA [cited 2020 May 11]. https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/milestones-us-food-and-drug-law-history.
- U.S. Food & Drug Administration. 2017. The FDA’s drug review process: ensuring drugs are safe and effective [Internet]. FDA [cited 2020 May 10]. https://www.fda.gov/drugs/drug-information-consumers/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective.
- U.S. Food & Drug Administration. 2018. Prescription Drug User Fee Act (PDUFA)—enhancing benefit-risk assessment in regulatory decision-making [Internet]. [cited 2020 Jul 4]. Available from: https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm326192.htm.
- U.S. Food & Drug Administration. Applications covered by Section 505(b)(2) [Internet]. 2020. U.S. Food and Drug Administration; [cited 2020 May 15]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2.
- U.S. Food & Drug Administration. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). FDA [Internet]. 2020. [cited 2020 Feb 12]. http://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.
- Wallace TC, Weaver CM. 2019. Calcium supplementation and coronary artery disease: a methodological confound? J Am Coll Nutr. 0:1–5.
- Wheeler M, Merten JW, Gordon BT, Hamadi H. 2020. CBD (cannabidiol) product attitudes, knowledge, and use among young adults. Subst Use Misuse. 55(7):1138–1145. doi:10.1080/10826084.2020.1729201.
- Woloshin S, Schwartz LM, White B, et al. 2017. The fate of FDA postapproval studies. Massachusetts Med Soc. [Internet]. [cited 2020 May 11]. https://www.nejm.org/doi/10.1056/NEJMp1705800.
- Wong CH, Siah KW, Lo AW. 2019. Estimation of clinical trial success rates and related parameters. Biostatistics. 20(2):273–286. doi:10.1093/biostatistics/kxx069.
- Xiao Q, Murphy RA, Houston DK, Harris TB, Chow W-H, Park Y. 2013. Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med. 173(8):639–646. doi:10.1001/jamainternmed.2013.3283.